Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) announced that U.S. Patent No. 12,577,232 was issued on March 17, 2026, covering its EVM301 Series of N-heterocycle substituted tryptamine derivatives.
The patent claims chemical compounds, pharmaceutical formulations, and methods for treating brain neurological disorders and expands coverage alongside U.S. Patent No. 12,338,231. Enveric cites lead candidate EB-003 and says it is progressing toward an IND submission and a first-in-human Phase 1 trial. The company reports a patent estate of 27 issued U.S. patents and approximately 60 pending national and international applications.
Enveric Biosciences (NASDAQ: ENVB) reported fourth-quarter and year‑end 2025 results and operational updates on March 27, 2026. Key points: positive preclinical data for EB-003 in models of severe chronic depression and PTSD, FDA feedback allowing a streamlined IND plan, multiple patent issuances and a withdrawn PGR petition, manufacturing CMC milestones, a 1-for-12 reverse stock split, and $4.7M cash on hand at year‑end.
The company raised $12.2M in fiscal 2025 (including $4.9M in Q4) and reported a Q4 net loss attributable to stockholders of $4.0M (loss per share $6.12).
Enveric Biosciences (NASDAQ: ENVB) announced that the Canadian Intellectual Property Office registered five trademarks, including house marks Enveric and Enveric Biosciences.
The registrations also cover two Plus Marks for product packaging and the trademark "Next Generation Mental Health". The company said it plans an IND filing for lead molecule EB-003 with the FDA in 2026.
Enveric Biosciences (NASDAQ: ENVB) announced that the Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against U.S. Patent No. 12,138,276 has been withdrawn and the PTAB granted the withdrawal, leaving no remaining challenges to the '276 patent.
The '276 patent covers halogenated psilocybin derivatives with claims relevant to bretisilocin (GM-2505), and the filing timeline cites events from August–November 2025 including AbbVie's up-to-$1.2 billion acquisition of bretisilocin from Gilgamesh.
Enveric Biosciences (NASDAQ: ENVB) reported proprietary BRET assay data showing its lead candidate EB-003 engages both Gq- and β-arrestin–mediated signaling downstream of the 5-HT2A receptor. The company said EB-003 shows a modest β-arrestin bias versus serotonin and that both pathways are engaged at biologically relevant levels. Enveric plans additional BRET testing including the Gi pathway and continues to advance EB-003 through IND-enabling studies.
Enveric Biosciences (NASDAQ: ENVB) announced that subsidiary Akos Biosciences licensed its US RCANN™ trademark portfolio and an RCANN design to TOTEC Pharma, an Aries affiliate, to support commercialization of a patented cannabinoid crème intended for radiation dermatitis.
The license includes an option to purchase the trademark portfolio if TOTEC meets specified development and commercialization milestones, and Enveric said the deal could lead to future milestone payments and royalties tied to product success.
Enveric Biosciences (NASDAQ: ENVB) announced on January 28, 2026 the closing of a registered direct offering of 328,802 common shares at $4.41 per share, generating approximately $1.5 million in gross proceeds. Concurrent private placements issued series G and H warrants to purchase up to 328,802 shares each.
The series G warrants have a $4.16 exercise price, are exercisable immediately and expire five years after the registration effective date; series H warrants have a $4.16 exercise price, are exercisable immediately and expire eighteen months after the registration effective date. Proceeds are intended for product development, working capital and general corporate purposes.
Enveric (NASDAQ: ENVB) announced a registered direct offering of 328,802 shares at $4.41 per share and concurrent private placement of two warrant series covering up to 328,802 shares each.
Gross proceeds are expected to be approximately $1.5 million before fees; series G and H warrants have $4.16 exercise prices and differing expiry terms.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of U.S. Patent No. 12,492,179 on December 29, 2025, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The patent claims compositions and treatment methods for novel, potentially neuroplastogenic and non‑hallucinogenic molecules, expands the company’s pipeline of patent‑protected candidates, and provides composition‑of‑matter protection intended to strengthen licensing and partnership prospects in neuropsychiatric, neurological, and addiction disorders.
ENvue Medical (NASDAQ: ENVB) announced on December 15, 2025 that David Johnson has been appointed Chairman of the Board. Johnson brings more than 30 years of healthcare leadership and board experience, including roles guiding Advanced Medical Balloons through acquisition and prior executive positions at ConvaTec and others.
The company said its 510(k) FDA-cleared feeding-tube placement system is in clinical use across 38 US hospitals, and management plans to increase hospital adoption in 2026 while pursuing additional 510(k) clearances to expand into neonatal and pediatric markets.